文献速递神经肿瘤

胶质瘤患者疫苗接种免疫应答与其他实体瘤及健康人的比较

Vaccine-induced immunity is maintained in glioma patients relative to other solid tumours.
PubMed 文献 · J Neurooncol · 2025-10-15

本研究在富胶质瘤人群中评估腺病毒DNA和mRNA新冠疫苗接种后的免疫应答,作为胶质瘤疫苗治疗的模型。共分析91名参与者,结果显示胶质瘤患者能产生有意义的免疫应答,记忆B细胞和T细胞反应与健康志愿者相似,提示胶质瘤疫苗治疗可行。

要点

  • 胶质瘤患者接种DNA和mRNA疫苗后可产生有意义的免疫应答。
  • 胶质瘤患者记忆B细胞和T细胞反应与健康志愿者相似。
  • 非胶质瘤实体瘤患者记忆B细胞和T细胞反应减低。

核心结论

  • 胶质瘤患者对DNA和mRNA疫苗能产生有意义的免疫应答,提示基于胶质瘤的疫苗治疗可行且值得进一步探索。

研究设计与样本

  • 采用ELISA和ELISPOT法评估SARS-CoV-2特异性免疫应答,共分析91名参与者。

主要发现

  • 第二剂接种后1个月,各组血清转化率无显著差异。
  • 至3个月时,胶质瘤和非胶质瘤患者的血清转化率显著低于健康志愿者。
  • 胶质瘤患者与健康志愿者的记忆B细胞和T细胞应答相似,而非胶质瘤患者应答降低。
  • 各队列疫苗效力相当。

临床怎么用

  • 胶质瘤患者可正常接种腺病毒载体或mRNA疫苗,不必因担心免疫应答不足而回避。
  • 胶质瘤疫苗治疗临床试验设计时可参考本研究采用的ELISA和ELISPOT免疫监测方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gliomas are the most common primary brain malignancy in adults, with treatment advances limited by challenges like the blood-brain barrier, tumour heterogeneity, and an immunosuppressive microenvironment. Tumour vaccines, such as adenoviral vector and mRNA-based vaccines, may overcome these barriers, but the ability of glioma patients to mount an immune response to these therapies remains unclear. This study assesses immune responses to adenoviral DNA and mRNA-based COVID-19 vaccinations in a glioma-enriched population as a model for glioma-based vaccine therapies. METHODS: COVID-19 naïve glioma and non-glioma solid tumour patients, along with healthy volunteers, were recruited between May 2021 and December 2022. Blood samples were collected at various time points: pre-vaccination, between the first and second doses, and at 1-, 3-, and 4-6-months post 2nd vaccination, including after a third booster dose. SARS-CoV-2 specific immune responses were evaluated using ELISA and ELISPOT assays. RESULTS: A total of 91 participants were analysed. At 1-month post 2nd vaccination, no significant differences in seroconversion rates were observed. By 3 months, glioma and non-glioma patients had significantly lower rates compared to healthy volunteers. Memory B and T cell responses were similar between glioma patients and healthy volunteers, but non-glioma patients showed decreased responses. Vaccine efficacy was comparable across all cohorts. CONCLUSION: This study demonstrates that glioma patients can mount meaningful immune responses to DNA and mRNA vaccines, suggesting that glioma-based vaccine therapies are feasible and warrant further exploration.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Yuile A, Wei JQ, McKelvey KJ, et al. Vaccine-induced immunity is maintained in glioma patients relative to other solid tumours. J Neurooncol. 2025. PMID: 41091287. doi:10.1007/s11060-025-05258-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。